[go: up one dir, main page]

HUP1900281A1 - Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra - Google Patents

Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra

Info

Publication number
HUP1900281A1
HUP1900281A1 HU1900281A HUP1900281A HUP1900281A1 HU P1900281 A1 HUP1900281 A1 HU P1900281A1 HU 1900281 A HU1900281 A HU 1900281A HU P1900281 A HUP1900281 A HU P1900281A HU P1900281 A1 HUP1900281 A1 HU P1900281A1
Authority
HU
Hungary
Prior art keywords
monoamine
oxidase
inhibitors
prevention
treatment
Prior art date
Application number
HU1900281A
Other languages
English (en)
Inventor
Gasznerne Dr Kormos Viktoria Dr
Kalai Tamas Dr
Mangel Laszlo Dr
Matyus Peter Dr
Anita Steib
Dr Helyes Zsuzsanna Tamasikne
Original Assignee
Toxie Europe Intelligens Kemiai Szenzorokat Kutato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxie Europe Intelligens Kemiai Szenzorokat Kutato filed Critical Toxie Europe Intelligens Kemiai Szenzorokat Kutato
Priority to HU1900281A priority Critical patent/HUP1900281A1/hu
Priority to PCT/HU2020/050035 priority patent/WO2021024005A1/en
Priority to US17/632,571 priority patent/US20220273588A1/en
Priority to CA3149678A priority patent/CA3149678A1/en
Priority to CN202080062420.6A priority patent/CN114375203A/zh
Priority to EP20797162.3A priority patent/EP4009963A1/en
Publication of HUP1900281A1 publication Critical patent/HUP1900281A1/hu
Priority to IL290328A priority patent/IL290328A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU1900281A 2019-08-06 2019-08-06 Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra HUP1900281A1 (hu)

Priority Applications (7)

Application Number Priority Date Filing Date Title
HU1900281A HUP1900281A1 (hu) 2019-08-06 2019-08-06 Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
PCT/HU2020/050035 WO2021024005A1 (en) 2019-08-06 2020-08-05 Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma
US17/632,571 US20220273588A1 (en) 2019-08-06 2020-08-05 Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma
CA3149678A CA3149678A1 (en) 2019-08-06 2020-08-05 Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma
CN202080062420.6A CN114375203A (zh) 2019-08-06 2020-08-05 在预防或治疗前列腺癌中使用的单胺氧化酶b抑制剂
EP20797162.3A EP4009963A1 (en) 2019-08-06 2020-08-05 Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma
IL290328A IL290328A (en) 2019-08-06 2022-02-03 Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1900281A HUP1900281A1 (hu) 2019-08-06 2019-08-06 Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra

Publications (1)

Publication Number Publication Date
HUP1900281A1 true HUP1900281A1 (hu) 2021-03-01

Family

ID=89992960

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1900281A HUP1900281A1 (hu) 2019-08-06 2019-08-06 Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra

Country Status (7)

Country Link
US (1) US20220273588A1 (hu)
EP (1) EP4009963A1 (hu)
CN (1) CN114375203A (hu)
CA (1) CA3149678A1 (hu)
HU (1) HUP1900281A1 (hu)
IL (1) IL290328A (hu)
WO (1) WO2021024005A1 (hu)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049478B1 (en) * 1998-01-13 2002-09-04 University of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
DE602005022826D1 (de) * 2005-02-18 2010-09-23 Universitaetsklinikum Freiburg Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1)
CN103826625A (zh) * 2011-07-26 2014-05-28 南加州大学 单胺氧化酶抑制剂及前列腺癌的治疗和诊断方法
US20180177786A1 (en) * 2011-07-26 2018-06-28 University Of Southern California Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
WO2013070526A1 (en) * 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP3062808B1 (en) * 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
US11459295B2 (en) * 2015-10-22 2022-10-04 The Trustees Of The University Of Pennsylvania 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same

Also Published As

Publication number Publication date
EP4009963A1 (en) 2022-06-15
WO2021024005A1 (en) 2021-02-11
CA3149678A1 (en) 2021-02-11
IL290328A (en) 2022-04-01
CN114375203A (zh) 2022-04-19
US20220273588A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
IL290011A (en) Ezh2 inhibition in combination therapies for cancer treatment
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL275949A (en) Combined treatment for the treatment of cancer or its prevention
ES3037813T3 (en) Usp7 inhibitor for use in the treatment of cancer
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
HUE071862T2 (hu) L718 és/vagy L792 mutáns, kezelésre rezisztens EGFR inhibitor rák kezelésében történõ alkalmazásra
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
IL276073A (en) Combined treatment for the treatment of cancer or its prevention
IL276074A (en) Combined treatment for the treatment of cancer or its prevention
IL275860A (en) Combined treatment for the treatment of cancer or its prevention
IL269121A (en) Usl-311 for use in the treatment of cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
HUP1900281A1 (hu) Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
IL280262A (en) Compositions and methods for treating cancer
IL311668A (en) A CYP11A1 inhibitor for use in the treatment of prostate cancer
HK40045582A (en) Extract of vegetation waters for use in the treatment and/or in the prevention of prostate cancer
HK40118235A (en) Quinoline derivatives for use in the treatment or prevention of cancer
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
AU2019902712A0 (en) Inhibitors and use thereof in cancer treatment
HK40022857B (en) Compounds for use in the therapeutic and/or prophylactic treatment of cancer

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished